AstraZeneca CEO Soriot touts M&A appetite as company weighs vaccine future: report Moderna co-founder helps finance Belgian mRNA shop Walmart expanding abortion coverage as employers navigate post-Roe landscape Abbott proclaims FDA approval of neurostimulator to treat pain in 6 areas at once Former Kadmon consultant pleads guilty to insider trading ahead of Sanofi buyout Windtree takes weight off branches, enters near $80M biobucks deal for acute pulmonary pipeline platform Medtronic still eyeing modest year-over-year growth as fiscal 2023 kicks off with slipping revenues Novartis set to eliminate many leadership positions as part of 1,400 layoffs in Switzerland Wyden probes marketing practices for Medicare Advantage, Part D plans Foghorn downgraded to full clinical hold, with more patient deaths clouding AML, MDS trial Gilead can't escape antitrust suit centered on pay-for-delay deal with Cipla, judge says CMS approves first measures to track social determinants at federal level Digital Diagnostics dials up $75M funding for diabetic retinopathy AI Featured Story | By Fraiser Kansteiner AstraZeneca’s adenovirus-based COVID shot Vaxzevria has walked in the shadow of mRNA giants during the pandemic. Now, the company is weighing whether to stick with vaccines at all. read more |
| |
|---|
|
Top Stories By Max Bayer Moderna co-founder Kenneth Chien is staying close to budding mRNA-based biotechs, investing in eTheRNA's latest 39 million euro series B. As a result, he'll join the company's board, alongside fellow investor and VC founder Marijn Dekkers. read more By Frank Diamond Walmart’s expansion of coverage for abortions made headlines. Health insurance companies have coverage questions, however. read more By Andrea Park A spinal cord stimulation device newly approved in the U.S. one-ups other pain relief devices—or, perhaps, six-ups them—by treating multiple areas of the body at once. read more By Zoey Becker A former Kadmon consultant pled guilty to insider trading ahead of Sanofi's September 2021 buyout of the small drugmaker. Frank Glassner made $368,000 trading off of nonpublic information, the feds say. read more By Gabrielle Masson Windtree Therapeutics is taking weight off its branches, entering a global licensing deal with Lee’s Pharmaceutical and Zhaoke Pharmaceutical that offers more than $78.9 million in potential biobucks for several acute pulmonary pipeline treatments. read more By Andrea Park Despite the waning effects of the pandemic and an intact device portfolio, Medtronic started a new fiscal year on a slightly sour note. read more By Kevin Dunleavy Of the 1,400 jobs Novartis plans to cut in its home country of Switzerland, up to half will be leadership positions, the company said during a media event Tuesday in Zurich. The news comes after the company revealed in June that it would slash 8,000 jobs in order to save $1 billion. read more By Robert King Sen. Ron Wyden, D-Oregon, is probing marketing practices for Medicare Advantage and Part D plans, asking state regulators for the most common sources of consumer complaints. read more By Max Bayer Three months after the FDA sent a warning to Foghorn via a partial clinical hold on its phase 1 trial, regulators have become even more dismayed, downgrading the company's study to a full hold in light of additional patient deaths. read more By Eric Sagonowsky Gilead is no stranger to antitrust lawsuits for its antiviral medicines, and now it's facing yet another in California. The Jacksonville Police Officers and Fire Fighters Health Insurance Trust is questioning the specifics of the company's 2014 patent settlement with Cipla. read more By Anastassia Gliadkovskaya The measure set was proposed by the Physicians Foundation and will be effective 2023. Hospitals will be required to report what portion of their population is screened for social drivers and how many screen positive in each category. read more By Andrea Park Not long after forging a partnership with Baxter earlier this year, Digital Diagnostics has roped in $75 million in series B funding to build out the reach of IDx-DR and its other AI-powered diagnostic tools, the company announced Tuesday. read more Resources Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Bio-Techne Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. |
